Start date: Apr 1, 2011,
End date: Mar 31, 2017
BTCure is based on the recognition that RA is a heterogeneous disease where a major subset involves adaptive immunity, and that animal models have to develop the line with the different subsets of the human diseases in order to be optimally used for drug discovery and drug evaluation. Our aim is to develop an understanding of the early process in human arthritis subsets and the animal models that will enable us and EFPIA partners to develop precise and eventually curative treatments to be used before a non-reversible destruction and function loss have occurred. The composition of the consortium include complementarities. Partners are involved to have large cohorts and biobank, to be excellent in understanding and modulating adaptive immunity, and to be able to take both these assets into clinical development of new therapeutics. The aim is to provide the basis for such development together with the EFPIA partners. All partners have a specific role in the development of specific technologies, mouse models, biobanks, systems for studying the adaptive immunity and drug development. Taken together the access for us and the EFPIA partners to this infrastructure and innovative projects will permit the development of new and innovative and ultimately curative therapies for early arthritis.
Get Access to the 1st Network for European Cooperation